On November 30, Shapuai Pharmaceutical issued an announcement that Mr.
Hu Zhengguo, a director of the company, applied to resign as a director of the company's fifth board of directors due to personal reasons
.
After his resignation, Mr.
Hu Zhengguo will continue to serve in other positions
in the Company.
On November 28, Jiangsu Wuzhong announced that the company recently received a written resignation report
from Zhang Shuaixin, vice president of the company.
Zhang Shuaixin applied to resign as vice president of the company due to personal reasons
.
After his resignation, Zhang Shuaixin will no longer hold any position
in the company.
Hansen Pharmaceutical also announced on November 28 that Ms.
Wang Xiaojuan applied to resign as the head of internal audit of
the company due to work reasons.
After resignation, you will not hold any position
in the company.
On November 16, YaoTesco announced that Hao Ruizhi recently applied to resign as the secretary of the company's board of directors and deputy general manager due to personal reasons
.
On November 15, Sinovac Pharmaceutical issued an announcement that Ms.
Shi Weijin applied to resign as the deputy general manager of the company due to personal reasons, and will no longer hold any position
in the company after her resignation.
.
.
.
.
.
.
Statistics show that as of November 17, more than 1,400 executives in the A-share biopharmaceutical industry have left the year, including executives from the Greater China region of multinational pharmaceutical companies, as well as a large number of executives of traditional pharmaceutical companies, as well as R&D leaders and founders of biopharmaceutical companies, involving 357 enterprises
.
It is worth mentioning that judging from the recent departure of executives from pharmaceutical companies, there are also "veterans" who have served in companies for many years have also chosen to leave
.
For example, China Biopharmaceutical announced on November 2 that director Wang Shanchun resigned
due to his intention to pursue other business development.
It is reported that Wang Shanchun has served as the executive director of China Biopharmaceutical since April 2015, and he has worked for CP Tianqing (the core subsidiary of China Biopharma) for more than 30 years, successively serving as deputy chief engineer, chief engineer, vice president, executive vice president, president and other positions, and successfully led the listing
of anlotinib innovative drugs.
In terms of whereabouts, on November 7, China Antibio Group announced the appointment of Wang Shanchun as the president of China Antibody Pharmaceutical China, responsible for the company's overall operation in Chinese mainland, mainly focusing on strategy formulation, strategic planning and management operations
.
It is understood that the main business of China Biopharmaceutical is modern preparations of traditional Chinese medicine and western medicine, and its products involve anti-tumor, cardiovascular and cerebrovascular, liver disease drugs, orthopedic drugs, respiratory system and parenteral nutrition drugs
.
Financial information shows that in 22Q3, the company achieved revenue of about RMB 7.
473 billion, a year-on-year increase of about 21.
3%.
In the first three quarters, the Group achieved cumulative revenue of about RMB22.
667 billion, a year-on-year increase of about 10.
5%.
The company said that the group is more focused on products with high innovation and high market potential, and expects the revenue of innovative drugs to account for 24%
in 2022.
China Antibody Pharmaceutical is an enterprise focusing on the research, development, manufacturing and commercialization of immunological disease therapies, mainly developing monoclonal antibody-based biological drugs
.
Among them, the blockbuster product SM03 is the world's first potential anti-CD22 monoclonal antibody for the treatment of rheumatoid arthritis, and has entered the phase III clinical trial
of rheumatoid arthritis in China.
In addition, there are a number of first-in-target and first-in-class potential drug candidates, some of which are already in the clinical stage, covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma and other diseases
with significant unmet clinical needs.
The immune market space in which the company is located is relatively broad
.
The change from a company that makes innovative drugs to a company that does immune drugs is just a microcosm
of the changes in senior management of pharmaceutical companies.
In the industry's view, the retention of pharmaceutical executives including some core talents has both active and passive reasons, and some talents may have their own considerations for their career planning and optimistic industry prospects, and it is expected that the changes will continue
at the end of the year.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
